Allstate Corporation’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-22,128
Closed -$4.97M 1421
2026
Q1
$4.97M Buy
22,128
+11,427
+107% +$2.85M 0.05% 239
2025
Q4
$2.58M Buy
10,701
+5,398
+102% +$1.38M 0.04% 310
2025
Q3
$1.45M Buy
+5,303
New +$1.45M 0.03% 289
2025
Q2
Sell
-2,734
Closed -$612K 486
2025
Q1
$612K Sell
2,734
-1,575
-37% -$368K 0.02% 467
2024
Q4
$985K Buy
+4,309
New +$1.04M 0.03% 314
2023
Q1
Sell
-6,016
Closed -$1.25M 487
2022
Q4
$1.25M Buy
6,016
+96
+2% +$21.1K 0.04% 300
2022
Q3
$1.29M Sell
5,920
-673
-10% -$153K 0.04% 272
2022
Q2
$1.38M Buy
6,593
+1,414
+27% +$301K 0.04% 255
2022
Q1
$1.26M Sell
5,179
-8,367
-62% -$2.02M 0.03% 354
2021
Q4
$3.53M Buy
13,546
+11,623
+604% +$3.02M 0.07% 242
2021
Q3
$507K Sell
1,923
-191
-9% -$52.2K 0.02% 507
2021
Q2
$521K Sell
2,114
-742
-26% -$156K 0.02% 511
2021
Q1
$554K Buy
2,856
+118
+4% +$23.7K 0.02% 512
2020
Q4
$582K Buy
2,738
+822
+43% +$164K 0.02% 451
2020
Q3
$328K Sell
1,916
-3,105
-62% -$573K 0.01% 547
2020
Q2
$964K Buy
+5,021
New +$821K 0.03% 256
2020
Q1
Sell
-10,453
Closed -$1.62M 675
2019
Q4
$1.62M Hold
10,453
0.03% 342
2019
Q3
$1.41M Hold
10,453
0.02% 339
2019
Q2
$1.28M Buy
+10,453
New +$1.16M 0.02% 359

Other funds holding RMD

Allstate Corporation's RMD Position: Q2 2026 in Review

Allstate Corporation sold out of ResMed (RMD) in Q2 2026, closing a stake of 22,128 shares — an estimated $4.97M sold.

Allstate Corporation first reported a position in RMD in Q2 2019 and held it in 19 quarters. The position peaked at $4.97M in Q1 2026. 880 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Allstate Corporation reported no remaining ResMed position as of Q2 2026 after selling out during the quarter.
  • Allstate Corporation sold 22,128 ResMed shares in Q2 2026, an estimated $4.97M.
  • Allstate Corporation first reported a position in ResMed in Q2 2019 and held it in 19 quarters.
  • Allstate Corporation's ResMed position peaked at $4.97M in Q1 2026.
  • 880 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Allstate Corporation's 13F filing for Q2 2026, filed 13 Aug 2026.